With DriverMap, Cellecta offers a novel, comprehensive end - to - end service portfolio for identifying differential gene expression, mapping of clinically actionable mutations in RNA,
detecting cellular composition, and profiling immunotherapy targets.
Not exact matches
The technology was also able to
detect cancer in marginal regions between normal and cancer tissues that presented mixed
cellular composition.
The transcriptional changes
detected above may partially be related to changes in the
cellular composition of blood triggered by death.